C7R-GD2.CART cell therapy (Baylor College of Medicine)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameC7R-GD2.CART cell therapy (Baylor College of Medicine)

Drug Alias NameC7R-GD2.CART细胞疗法-贝勒医学院

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionDisialoganglioside GD2 modulatorsT lymphocyte replacements

TargetsDisialoganglioside GD2

Therapy Area/IndicationsDiffuse Intrinsic Pontine GliomaGliomaNeoplasms, Germ Cell and Embryonal

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBaylor College Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesBaylor College Of Medicine

Inactive CompaniesN/A

Active IndicationsDiffuse Intrinsic Pontine GliomaGliomaNeoplasms, Germ Cell and Embryonal

Inactive IndicationsN/A

Other Information

ATC CodeN/A